vs
Side-by-side financial comparison of Laird Superfood, Inc. (LSF) and MODIV INDUSTRIAL, INC. (MDV). Click either name above to swap in a different company.
Laird Superfood, Inc. is the larger business by last-quarter revenue ($13.3M vs $11.1M, roughly 1.2× MODIV INDUSTRIAL, INC.). MODIV INDUSTRIAL, INC. runs the higher net margin — 11.0% vs -13.2%, a 24.1% gap on every dollar of revenue. On growth, Laird Superfood, Inc. posted the faster year-over-year revenue change (15.0% vs -5.6%). Over the past eight quarters, Laird Superfood, Inc.'s revenue compounded faster (16.1% CAGR vs -3.8%).
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
MODIV INDUSTRIAL, INC. is a U.S.-based industrial real estate enterprise focused on acquiring, owning and operating high-quality industrial properties mainly located in key logistics and distribution hubs across North America. It serves tenants from sectors including e-commerce fulfillment, manufacturing and third-party logistics, addressing rising demand for modern supply chain infrastructure.
LSF vs MDV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $11.1M |
| Net Profit | $-1.8M | $1.2M |
| Gross Margin | 34.1% | — |
| Operating Margin | -13.5% | 45.8% |
| Net Margin | -13.2% | 11.0% |
| Revenue YoY | 15.0% | -5.6% |
| Net Profit YoY | -341.4% | -22.0% |
| EPS (diluted) | — | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | $11.1M | ||
| Q3 25 | $12.9M | $11.7M | ||
| Q2 25 | $12.0M | $11.8M | ||
| Q1 25 | $11.7M | $11.8M | ||
| Q4 24 | $11.6M | $11.7M | ||
| Q3 24 | $11.8M | $11.7M | ||
| Q2 24 | $10.0M | $11.4M | ||
| Q1 24 | $9.9M | $12.0M |
| Q4 25 | $-1.8M | $1.2M | ||
| Q3 25 | $-975.1K | $1.0M | ||
| Q2 25 | $-362.2K | $-2.0M | ||
| Q1 25 | $-156.2K | $829.0K | ||
| Q4 24 | $-398.4K | $1.6M | ||
| Q3 24 | $-166.1K | $-587.0K | ||
| Q2 24 | $-239.1K | $1.3M | ||
| Q1 24 | $-1.0M | $3.7M |
| Q4 25 | 34.1% | — | ||
| Q3 25 | 36.5% | — | ||
| Q2 25 | 39.9% | — | ||
| Q1 25 | 41.9% | — | ||
| Q4 24 | 38.6% | — | ||
| Q3 24 | 43.0% | — | ||
| Q2 24 | 41.8% | — | ||
| Q1 24 | 40.0% | — |
| Q4 25 | -13.5% | 45.8% | ||
| Q3 25 | -7.7% | 41.4% | ||
| Q2 25 | -3.3% | 9.8% | ||
| Q1 25 | -1.9% | 40.2% | ||
| Q4 24 | -4.1% | 45.4% | ||
| Q3 24 | -2.3% | 42.0% | ||
| Q2 24 | -3.4% | 44.6% | ||
| Q1 24 | -11.0% | 55.6% |
| Q4 25 | -13.2% | 11.0% | ||
| Q3 25 | -7.6% | 9.0% | ||
| Q2 25 | -3.0% | -17.1% | ||
| Q1 25 | -1.3% | 7.0% | ||
| Q4 24 | -3.4% | 13.3% | ||
| Q3 24 | -1.4% | -5.0% | ||
| Q2 24 | -2.4% | 11.6% | ||
| Q1 24 | -10.3% | 31.1% |
| Q4 25 | — | $0.02 | ||
| Q3 25 | — | $0.00 | ||
| Q2 25 | — | $-0.32 | ||
| Q1 25 | — | $-0.01 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 24 | — | $0.03 | ||
| Q1 24 | — | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.1M | $14.4M |
| Total DebtLower is stronger | — | $261.5M |
| Stockholders' EquityBook value | $11.5M | $162.7M |
| Total Assets | $19.2M | $476.5M |
| Debt / EquityLower = less leverage | — | 1.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | $14.4M | ||
| Q3 25 | $5.1M | $8.3M | ||
| Q2 25 | $3.9M | $5.8M | ||
| Q1 25 | $7.0M | $6.2M | ||
| Q4 24 | $8.3M | $11.5M | ||
| Q3 24 | $7.9M | $6.8M | ||
| Q2 24 | $7.6M | $18.9M | ||
| Q1 24 | $7.1M | $18.4M |
| Q4 25 | — | $261.5M | ||
| Q3 25 | — | $279.7M | ||
| Q2 25 | — | $279.7M | ||
| Q1 25 | — | $279.7M | ||
| Q4 24 | — | $279.8M | ||
| Q3 24 | — | $279.7M | ||
| Q2 24 | — | $279.7M | ||
| Q1 24 | — | $279.6M |
| Q4 25 | $11.5M | $162.7M | ||
| Q3 25 | $12.8M | $164.8M | ||
| Q2 25 | $13.4M | $165.6M | ||
| Q1 25 | $13.3M | $171.1M | ||
| Q4 24 | $13.2M | $190.1M | ||
| Q3 24 | $13.1M | $186.3M | ||
| Q2 24 | $12.6M | $187.0M | ||
| Q1 24 | $12.7M | $188.0M |
| Q4 25 | $19.2M | $476.5M | ||
| Q3 25 | $18.9M | $499.6M | ||
| Q2 25 | $20.4M | $498.9M | ||
| Q1 25 | $21.5M | $506.8M | ||
| Q4 24 | $19.3M | $507.8M | ||
| Q3 24 | $18.8M | $507.4M | ||
| Q2 24 | $18.0M | $519.5M | ||
| Q1 24 | $17.6M | $522.5M |
| Q4 25 | — | 1.61× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.69× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | — | 1.50× | ||
| Q2 24 | — | 1.50× | ||
| Q1 24 | — | 1.49× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $68.4K | $15.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 12.34× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.4K | $15.0M | ||
| Q3 25 | $1.2M | $4.1M | ||
| Q2 25 | $-2.8M | $3.9M | ||
| Q1 25 | $-1.3M | $3.0M | ||
| Q4 24 | $339.2K | $18.2M | ||
| Q3 24 | $305.8K | $5.1M | ||
| Q2 24 | $642.7K | $4.7M | ||
| Q1 24 | $-422.3K | $3.0M |
| Q4 25 | — | 12.34× | ||
| Q3 25 | — | 3.95× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.68× | ||
| Q4 24 | — | 11.72× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.55× | ||
| Q1 24 | — | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
MDV
Segment breakdown not available.
